Definitive Contract 75F40118C10184
Award Date 9/19/18
Potential Completion Date 12/30/22
Potential Value $1.6M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Tucson, AZ 85718, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $787,013 cost-reimbursement contract awarded by the Food and Drug Administration (FDA) to The Critical Path Institute (C-Path), a non-profit organization, for the "Clinical Evaluation and Qualification of Translational Kidney Safety Biomarkers." The contract, which does not have a set-aside designation, was awarded on September 8, 2016 and has a completion date of June 29, 2019. C-Path's work under this contract involves collaborating with industry, academia, and patient...
- This is a definitive, firm fixed-price federal contract awarded by the Food and Drug Administration (FDA) to the non-profit organization The Critical Path Institute (C-Path), doing business as C-Path. The contract, which is not set aside for specific business types, has a ceiling value of $3,376,000.00 and a completion date of August 21, 2028. The contract is for the development of drug development tools for autosomal dominant tubulointerstitial kidney disease (ADTKD). C-Path, the prime...
- This is a definitive contract awarded by the Department of Health and Human Services' Food and Drug Administration (FDA) to The Critical Path Institute (C-Path), a nonprofit organization, to provide services in support of the agency's Model-Informed Drug Development (MIDD) program for the evaluation and development of neurological drug products. The $1,128,848.00 firm fixed-price contract has an anticipated completion date of August 31, 2023. C-Path has previously supported the FDA's...
- This federal contract award is for $4,418,256.96 to The Critical Path Institute (C-Path), a non-profit organization, by the Food and Drug Administration (FDA). The contract was awarded under the FDA's Broad Agency Announcement (BAA) EETWP #63 to develop "A STANDARDIZED FRAMEWORK TO SUPPORT FDA QUALIFICATION OF COMPLEX IN VITRO MODELS FOR USE IN REGULATORY SUBMISSIONS." The BAA solicits research and development proposals to advance regulatory science in various areas of interest for...
- This federal contract award, valued at $977,245.04, was issued by the National Cancer Institute, a civilian agency, to Pathrx, Inc., a small disadvantaged business. The award is for research and development in the biomedical (basic research) domain, with a period of performance ending on September 21, 2017. The contract type is a Definitive Contract with a Cost Plus Fixed Fee pricing structure, and there was no set-aside designation used. The place of performance is East Watertown, MA 02472.
- This is a $1,904,355.00 definitive cost-no-fee contract awarded by the Food and Drug Administration (FDA), a civilian government agency, to the Institute Of Quantitative Systems Pharmacology, a non-profit organization. The contract is for basic and applied research with two key objectives: (1) to test the hypothesis that variabilities in nanoparticle (NP) properties and tumor targets cause uncertainties in "FORMULA", and (2) to develop computational models to predict the...
- Toxicologic Pathology Associates Inc. was awarded a $20.7 million definitive contract by the Department of Health and Human Services' Food and Drug Administration to provide onsite pathology services from July 2015 through July 2020. The contract has a small business set aside designation. As part of its mission to protect public health, the FDA utilizes pathology expertise to evaluate samples for issues impacting medical products and the safety of the food supply. This award draws on the...
- The U.S. Food and Drug Administration (FDA) awarded a $1,845,195.00 firm fixed price delivery order contract to Biopharma Services USA Inc., a foreign-owned small disadvantaged business, to conduct a randomized, open-label, two-treatment, four-period, single-dose, fully replicate, crossover bioequivalence (BE) study of tacrolimus capsules 5 mg. This task order was issued under an Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the ID HHSF223201610004I. The contract has a May 31,...
- The Food and Drug Administration (FDA) awarded a $724.5K definitive firm fixed-price contract to PPD Development LP on September 11, 2024, for development of a patient-reported outcome (PRO) burden measure focused on Cardiovascular-Kidney-Metabolic (CKM) syndrome. The contract, designated FDABAA-24-00123 with reference number FY24C1EP6, runs through November 15, 2026, and will be performed in Cape Fear, North Carolina. This contract represents a targeted effort to establish standardized...
- The U.S. Food and Drug Administration (FDA) awarded a $19,731,473.00 definitive contract to Zata Pharmaceuticals, Inc. for the development and maintenance of FDA-ARGOS 2 universal closed systems for pathogen reduction in donated whole blood units. This contract, awarded on September 27, 2021, has a completion date of September 26, 2025 and does not have a set-aside designation. The contract was issued under the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits...